查詢結果分析
相關文獻
- Comparison of Clinical Outcomes between the Gonadotropin-Releasing Hormone (GnRH) Antagonist, Cetrorenix, and the GnRH Agonist, Buserelin, during Controlled Ovarian Hyperstimulation in In Vitro Fertilization and Intracyto Plasmic Sperm Injection
- 伊甸園能重整嗎?--論現代人焦慮之根源[評Lee M. Sliver, «Remaking Eden: Cloning and Beyond in a Brave Now World»]
- 我要作人工生殖(治療手冊)(2)--試管嬰兒篇
- 試管嬰兒 : 受生的或製造的?
- 接受試管嬰兒治療之不孕症婦女在不同治療過程的心理社會反應
- 受精卵法律地位之探索
- 初次與重覆接受試管嬰兒治療不孕症夫妻之心理社會反應
- 快速分裂胚胎在試管嬰兒治療中的臨床意義
- 在IVF或ICSI治療中,前瞻性及隨機分佈研究使用兩種不同r-FSH製劑(Gonal-F[feb9], Puregon[feb9])的結果
- Neonatal Outcome of Infants Born after in Vitro Fertilization at National Taiwan University Hospital
頁籤選單縮合
題 名 | Comparison of Clinical Outcomes between the Gonadotropin-Releasing Hormone (GnRH) Antagonist, Cetrorenix, and the GnRH Agonist, Buserelin, during Controlled Ovarian Hyperstimulation in In Vitro Fertilization and Intracyto Plasmic Sperm Injection=比較性腺激素釋放激素拮抗劑Cetrorenix與衍生劑Buserelin於試管嬰兒控制性卵巢刺激時之臨床效果 |
---|---|
作 者 | 張惠雯; 楊爵閣; 謝佳霓; 林國城; | 書刊名 | 臺灣婦產科醫學會會刊雜誌 |
卷 期 | 42:3 2003.09[民92.09] |
頁 次 | 頁179-185 |
分類號 | 417.125 |
關鍵詞 | 試管嬰兒; 顯微授精; GnRH antagonist; GnRH agonist; In vitro fertilization; IVF; Intracytoplasmic sperm injection; ICSI; |
語 文 | 英文(English) |
中文摘要 | 目的:本研究之主要目的在比較性腺激素釋放激素拮抗劑cetrorenix與衍生劑buserelin在試管嬰兒控制性卵巢刺激時之臨床效果。材料和方法:50對不孕夫妻,在試管嬰兒治療刺激卵巢時施打cetrorenix共57週期(第一組)。56對不孕夫妻,在試管嬰兒治療刺激卵巢時給予buserelin共68週期(第二組)。刺激排卵時,兩組均以FSH和HMG從月經第三天開始注射,依個人之卵巢反應做各種劑量之調整。臨床結果之評估以取卵數、受精卵數、分裂胚胎數及臨床懷孕率來比較兩組之成效。結果:第二組之取卵數及成熟卵數比第一組多,但無統計學上之差異。二組間受精率及分裂胚胎之數量有類似之結果。在臨床懷孕率與繼續懷孕率上,第一組稍為比第二組高,但無統計上之差異。二組間之週期取消率與卵巢過度刺激症候群之發生率亦無差別。結論:在試管嬰兒之控制性卵巢刺激週期上,多劑量之cetrorenix與目前臨床常用之buserelin相較,具相似的有效性與安全性。 |
英文摘要 | Objective: To compare clinical outcomes between the gonadotropin-releasing hormone (GnRH) antagonist, cetrorenix; and the GnRH agonist, buserelin, during controlled ovarian hyperstimulation (COH) in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) treatment. Material(s) and Method(s): This study was conducted on 57 cycles in 50 couples who used cetrorenix (group I) and on 68 cycles in 56 couples who used buserelin (group II) and were undergoing COH for IVF and ICSI programs. Recombinant FSH and human chorionic gonadotropin were administered for superovulation from cycle day 3 on an individual basis according to the ovarian response. Numbers of oocytes retrieved, oocytes fertilized, and cleaved embryos and pregnancy rates were compared between the two groups. Result(s): Numbers of oocytes and metaphase II oocytes retrieved in group II did not significantly differ from those in group I. The fertilization rate of metaphase II oocytes after insemination in group I (6.7 ± 0.6) was comparable with that of group II (7.3 ± 0.5). The clinical pregnancy rate and ongoing pregnancy rate were higher in group I (42.1% and 33.3%) than in group II (38.2% and 27.9%, respectively), but did not statistically significantly differ. No cancellation cycle occurred in either group. There was one instance of ovarian hyperstimulation syndrome (OHSS) observed in each group during the study. Conclusion(s): A multiple dose of the GnRH antagonist, cetrorenix, is as effective, efficient, and safe for COH as the long protocol of the GnRH agonist, buserelin, during IVF and ICSI treatment. |
本系統中英文摘要資訊取自各篇刊載內容。